Inverse Correlation between Expression Levels of p27 and the Ubiquitin Ligase Subunit Skp2 in Early Esophageal Squamous Cell Carcinoma

Anticancer Research

Volumn 24, Issue 2 B, 2004, Pages 777-783

  Fukuchi, Minoru ^a   Masuda, Norihiro ^a   Nakajima, Masanobu ^a   Fukai, Yasuyuki ^a   Miyazaki, Tatsuya ^a   Kato, Hiroyuki ^a   Kuwano, Hiroyuki ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Esophageal squamous cell carcinoma; Immunohistochemistry; P27; Skp2; Western blotting

Indexed keywords

PROTEIN P27; S PHASE KINASE ASSOCIATED PROTEIN 2; UBIQUITIN PROTEIN LIGASE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME DEGRADATION; ENZYME SUBUNIT; ESOPHAGUS; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; WESTERN BLOTTING;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P27; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; RNA, MESSENGER; S-PHASE KINASE-ASSOCIATED PROTEINS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN;

EID: 2442585597     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Carrano AC, Eytan E, Hershko A and Pagano M: Skp2 is required for ubiquitin-mediated degradation of the Cdk inhibitor p27. Nat Cell Biol 1: 193-199, 1999.
2. KiP1 degradation and induces S phase in quiescent cells. Nat Cell Biol 1: 207-214, 1999.
3. Tsvetkov LM, Yeh KH, Lee SJ et al: p27 (Kip1) ubiquitination and degradation is regulated by the SCF-(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol 9: 661-664, 1999.
4. Laney JD and Hochstrasser M: Substrate targeting in the ubiquitin system. Cell 97: 427-430, 1999.
5. Skp2 essential elements of the cyclinA-Cdk2 S phase kinase. Cell 82: 915-925, 1995.
6. Deshaies R: SCF and Cullin/Ring H2 based ubiquitin ligases. Annu Rev Cell Dev Biol 15: 435-467, 1999.
7. Kip1, polyploidy and centrosome overduplication. EMBO J 19: 2069-2081, 2000.
8. Skp2 and E2F-1 underlines the regulation of E2F-1 degradation. Nat Cell Biol 1: 14-19, 1999.
9. CIP1/WAF1 and cyclin D proteins. Proc Natl Acad Sci USA 95: 11324-11329, 1998.
10. KiP1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Develop 8: 9-22, 1994.
11. KiP1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78: 59-66, 1994.
12. Toyoshima H and Hunter T: p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78: 67-74, 1994.
13. Pagano M, Tam SW, Theodoras AM et al: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science (Wash. DC) 296: 682-685, 1995.
14. Gstaiger M, Jordan R, Lim M et al: Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci USA 98: 5043-5048, 2001.
15. Kudo Y, Kitajima S, Sato S et al: High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas. Cancer Res 61: 7044-7047, 2001.
16. KiP1 and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. Cancer 91: 1745-1751, 2001.
17. Masuda TA, Inoue H, Sonoda H et al: Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res 62: 3819-3825, 2002.
18. Yang G, Ayala G, Marzo AD et al: Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res 8: 3419-3426, 2002.
19. Ohashi Y, Sasano H, Yamaki H et al: Cell cycle inhibitory protein p27 in esophageal squamous cell carcinoma. Anticancer Res 19: 1843-1848, 1999.
20. KiP1 expression predicts poor prognosis in patients with esophageal squamous cell carcinoma. Oncology 58: 152-158, 2000.
21. KIP1 expression and progression of human esophageal cell carcinoma. Int J Cancer 79: 439-443, 1998.
22. KIP1 and cyclinD1 expression esophageal cancer. Oncology 57: 311-317, 1999.
23. KiP1 in esophageal cell carcinomas. Dis Esophagus 13: 179-184, 2000.
24. Fukuchi M, Masuda N, Miyazaki T et al: Decreased Smad4 expression in the transforming growth factor-β signaling pathway during progression of esophageal squamous cell carcinoma. Cancer 95: 737-743, 2002.
25. Nishihira T, Hashimoto Y, Katayama M et al: Molecular and cellular features of esophageal cancer cells. J Cancer Res Clin Oncol 119: 441-449, 1993.
26. Fukuchi M, Imamura T, Chiba T et al: Ligand-dependent degradation of Smad3 by a ubiquitin ligase complex of ROC1 and associated proteins. Mol Biol Cell 12: 1431-1443, 2001.
27. KIP1 protein in human esophageal cancer cell lines that overexpress cyclinD1. Carcinogenesis 18: 1139-1148, 1997.